

Comparison of second-line hormonal agents medroxyprogesterone acetate and aminoglutethimide in advanced breast cancer

Submission date 19/08/2002	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 19/08/2002	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 27/01/2015	Condition category Cancer	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

--

Contact details

UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

Protocol serial number

BR3004

Study information

Scientific Title

Comparison of second-line hormonal agents medroxyprogesterone acetate and aminoglutethimide in advanced breast cancer

Study objectives

Not provided at time of registration.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration.

Primary study design

Interventional

Study design

Randomised controlled trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Breast cancer

Interventions

Patients are randomised to receive either:

1. Group A: Medroxyprogesterone acetate 250 mg four times daily until disease progression or failure of treatment.
2. Group B: Aminoglutethimide 250 mg twice daily plus hydrocortisone 20 mg twice daily until disease progression or failure of treatment. There is a crossover option on disease progression or failure of treatment.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Medroxyprogesterone acetate, aminoglutethimide, hydrocortisone

Primary outcome(s)

Not provided at time of registration.

Key secondary outcome(s)

Not provided at time of registration.

Completion date

01/08/1996

Eligibility**Key inclusion criteria**

1. Advanced breast cancer
2. Relapsed or failed following tamoxifen treatment
3. Postmenopausal

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex

Not Specified

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/08/1991

Date of final enrolment

01/08/1996

Locations**Countries of recruitment**

United Kingdom

England

Study participating centre

UKCCCR Register Co-ordinator

London

United Kingdom

NW1 2DA

Sponsor information**Organisation**

Ciba-Geigy Pharmaceuticals (Switzerland)

ROR

<https://ror.org/02f9zrr09>

Funder(s)

Funder type

Industry

Funder Name

Ciba-Geigy Pharmaceuticals, Farmitalia Carlo Erba

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration